Published in Int J Clin Exp Pathol on November 01, 2015
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods (2008) 126.81
RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77
The transcriptional landscape of the yeast genome defined by RNA sequencing. Science (2008) 48.99
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science (2008) 29.99
The impact of next-generation sequencing technology on genetics. Trends Genet (2008) 21.07
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
RNA sequencing: advances, challenges and opportunities. Nat Rev Genet (2010) 8.96
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res (2011) 5.58
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Dynamic instability of microtubules as an efficient way to search in space. Proc Natl Acad Sci U S A (1994) 2.25
CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J (2000) 1.45
Multifunctional roles of gelsolin in health and diseases. Med Res Rev (2010) 1.42
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg (2015) 1.33
Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res (1995) 1.33
Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene (2000) 1.28
Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet (2011) 1.27
RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One (2011) 1.18
Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer (1999) 1.18
Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res (1998) 1.16
Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retard apoptotic progression. J Biol Chem (2000) 1.13
Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One (2012) 1.08
Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer (2005) 1.07
Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer (2002) 1.06
Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology (2003) 1.05
Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res (2001) 1.03
Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat (2001) 1.03
Transcriptome profiling in neurodegenerative disease. J Neurosci Methods (2010) 1.02
Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate (1999) 1.01
In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol (2008) 0.99
Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Oncogene (1993) 0.99
Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS. Neoplasma (2014) 0.99
The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med (2008) 0.97
Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol (1989) 0.97
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol (2004) 0.95
Genome-wide analyses of Epstein-Barr virus reveal conserved RNA structures and a novel stable intronic sequence RNA. BMC Genomics (2013) 0.93
Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun (2011) 0.92
Predominant induction of gelsolin and actin-binding protein during myeloid differentiation. J Biol Chem (1988) 0.90
Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol (2006) 0.87
Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. J Proteomics (2012) 0.84
Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer. Endocrinology (2006) 0.83
Tissue distribution and levels of gelsolin mRNA in normal individuals and patients with gelsolin-related amyloidosis. FEBS Lett (1997) 0.83
Aging-associated increase of gelsolin for apoptosis resistance. Biochem Biophys Res Commun (2003) 0.83
Transcriptome analyses to investigate the pathogenesis of RNA splicing factor retinitis pigmentosa. Adv Exp Med Biol (2012) 0.82
Modulation of gelsolin content in rat aortic smooth muscle cells during development, experimental intimal thickening and culture. An immunohistochemical and biochemical study. Eur J Biochem (1990) 0.81
Biphasic pattern of gelsolin expression and variations in gelsolin-actin interactions during myogenesis. Exp Cell Res (1995) 0.79
Ezrin, actin and cytoskeleton in apoptosis of esophageal epithelial cells induced by arsenic trioxide. Int J Mol Med (2003) 0.78
Prognostic impact of hepatectomy for patients with non-hepatitis B, non-hepatitis C hepatocellular carcinoma. Anticancer Res (2014) 0.77